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ABSTRACT 
 
Background:  Type II diabetes is characterized by hyperglycemia, insulin 
resistance or having impairment with insulin secretion.  Patients are traditionally 
treated with oral medication and lifestyle modification before adding insulin to 
their treatment.  Exenatide is an adjunct subcutaneous therapy to improve 
glycemic control and weight loss 
 
Method:  The focus of this study was to review clinical trials of exetanide on 
diabetes mellitus type II.  A thorough review of clinical trials from 2000 to 2010, 
pertaining to exetanide versus standard oral hypoglycemic were selected and 
analyzed.  One double-blind, two triple-blind, and randomized control trials were 
identified by systematic literature search using PubMed, Cochrane, Medline and 
CINHAL search engines. The comprehensive literature search resulted in a total 
of 36 articles that were analyzed thoroughly, but only three articles were chosen.  
 
Results:  The 30 week study from DeFronzo et al. (2005) demonstrate HbA(1c) 
changes from baseline +/- SE for each group were -0.78 +/- 0.10% (10 microg), -
0.40 +/- 0.11% (5 microg), and +0.08 +/- 0.10% (placebo; intent to treat; adjusted 
P < 0.002).  The Buse et al. study show HbA(1c) changes from baseline were -
0.86 +/- 0.11, -0.46 +/- 0.12, and 0.12 +/- 0.09% (+/-SE) in the 10-microg, 5-
microg, and placebo arms, respectively (adjusted P < 0.001).  Zinman et al. 16 
week study demonstrate a mean HbA1c decrease of 0.89% ± 0.09% in the 
exenatide group (p<0.001) 
  
Conclusion:  Exenatide demonstrates improved glycemic control, reduced body 
weight, and reduced fasting blood glucose in type II diabetic patients who have 
failed to achieve glycemic control with traditional oral hyperglycemic medications 
 
Keywords:  Diabetes Type II, exenatide, metformin, sulfonylurea, and 
thiazolidinedione 
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INTRODUCTION 
Background 
 Diabetes mellitus (DM) is a metabolic disorder that is characterized 
by impaired insulin secretion and varying degrees of insulin resistance that lead 
to hyperglycemia.  Years of uncontrolled diabetes may result in macrovascular 
and microvascular complications that affect the heart, kidneys, and eyes.  In 
addition, uncontrolled hyperglycemia can also lead to neuropathic complications 
that can cause numbing and loss of sensation in distal extremities.  In lower 
extremities, blunted perception of foot trauma from ill-fitting shoes or abnormal 
weight bearing often leads to foot ulceration and fractures. The increased 
cardiovascular risk associated with DM contributes to it being the sixth leading 
cause of death in the US (National Diabetes Information Clearinghouse, 2007).  
For every 1% increase in glycosylated hemoglobin (HbA1c) above 5%, there is a 
20% epidemiological increase in cardiovascular risk (Khaw et al., 2004).  The 
financial impact of DM in 2007 was estimated to be US$174 billion (direct 
medical costs and indirect costs resulting from lack of employee productivity) 
(American Diabetes Association, 2007).  Worldwide, the total number of people 
with DM is projected to increase from 171 million in 2000 to 366 million in 2030 
(Wild, Roglic, Green, Sicree, King, 2004). These important statistics demonstrate 
that there is a diabetic epidemic on the rise and it is essential that patients are 
educated about their disease and the proper management of diabetes mellitus. 
Diabetes mellitus is treated with diet and exercise, coupled with oral 
hypoglycemic medications, insulin sensitizers, medications that impede hepatic 
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production of glucose and prescribed insulin. However, hypoglycemia, 
gastrointestinal side effects, weight gain, and lack of optimal control of 
postprandial glucose are limitations that may present with the use of these type II 
DM treatments, preventing patients from reaching glycemic control.  Exenatide, 
an incretin-mimetic subcutaneous injection, is an adjunct medication that can 
significantly lower hemoglobin A1c, body weight, and postprandial glucose 
excursions in humans and significantly improve β -cell function.  It has biological 
effects that slow gastric emptying and decrease appetite (Van Gaal, Gutkin &, 
Nauck, 2008).  This paper comprehensively analyzes research that compares 
exenatide to traditional oral medications that treat diabetes mellitus type II.     
 
Purpose of the Study 
 This paper focuses on the current literature on the clinical efficacy and 
safety of exenatide on the treatment of type II diabetes mellitus and analyzes the 
medication’s purpose in reducing HbA1c and weight loss.  It is a systematic 
review of the literature that examines exenatide compared to traditional 
medications that treat DM II.  This paper also uses the GRADE criteria to score 
the strength of evidence of the literatures used in this research.    
 
 
 
 
METHODS 
 
An extensive literature search was conducted for recent studies on 
exenatide for Type II Diabetes Mellitus.  The PubMed, Cochrane, Medline and 
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CINHAL databases were accessed through the Pacific University Library system. 
The keywords searched included “diabetes type II”, “exenatide”, “sulfonylurea”, 
“thiazolidinedione”, and “metformin”. The search was limited to adults; 19+ years, 
human subjects, the English language, free full text articles, and randomized 
controlled trials.  The initial results included 36 articles. Articles older than the 
year 2000 were excluded. Only randomized, controlled trials were reviewed.  In 
addition, articles that did not compare exenatide with traditional oral medications 
for diabetes were excluded.  This resulted in three studies to review. 
RESULTS 
 DeFronzo et al. (2005) studied the effects of adding exenatide to 
metformin to improve glycemic control.  The study population was well balanced 
across the three treatment arms.  The intent-to-treat was comprised of 336 
subjects with 272 subjects completing the study and 64 withdrawing early.  The 
subjects were between the ages of 19-72 years of age.  Inclusion criteria were 
fasting plasma glucose concentration of < 13.3 mmol/l (<240mg/dl), BMI of 27-45 
kg/m2 and HbA1c of 7.1-11.0%.  Subjects had to have been using metformin at a 
dose of equal, to or greater than, 1,500mg/day for at least three months before 
screening.  Stable weight for three months was also a part of the inclusion 
criteria.  Subjects were excluded if they had used sulfonylurea, meglitinides, 
thiazolinediones, alpha-glucosidase inhibitors, exogenous therapy, weight loss 
drugs, corticosteroid drugs, drugs known to affect gastrointestinal motility, 
transplantation medication, or had evidence of clinically significant co-morbid 
conditions for three months before screening.   
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The study from DeFronzo et al. (2005) had three treatment arms that 
analyzed patients on metformin and exenatide or placebo.  Metformin was at a 
stable dose on all three arms. Subjects that were receiving 10mg exenatide arm 
and 5mg exenatide arm received the study medication twice daily.   At week 30, 
40% (41 subjects) in 10mg exenatide arm and 27% (27 subjects) in 5mg 
exenatide arm, with a baseline HbA1c greater than 7%, had reached an HbA1c 
less than or equal to 7%. The results in the evaluable population also had similar 
findings.  Forty-six percent of the subjects in the 10mg exenatide arm and 32% of 
subjects in the 5mg exenatide arm had achieved an HbA1c of less than or equal 
to 7% by week 30.  Fasting plasma glucose levels at week 30 were –0.6 ± 0.2 
mmol/l (-10.1 ± 4.4 mg/dl; p= 0.0001) and -0.4 ± 0.3 mmol/l (-7.2 ± 4.6 mg/dl; p < 
0.005) for the 10 mg and 5mg exenatide arms, respectively, compared with +0.8 
± 0.2 mmol/l  (+14.4 ± 4.2 mg/dl) for the placebo arm.  In addition, body weight 
on exenatide arms demonstrates progressive weight loss from baseline.  The 
most frequent adverse reaction from the study was mild to moderate in intensity, 
with the incidence of sever nausea (3.5&, 2.7%, and 1.8% in the 10-mg, 5-mg, 
and placebo arms, respectively).    Nausea was reported to be at a higher 
incidence during week 0-8 and declined thereafter.  There were no cases of 
severe hypoglycemia.  The overall hypoglycemic events were 5.3% (six subjects) 
in the 10-mg exenatide arm, 4.5% (five subjects) in the 5-mg exenatide arm, and 
5.3% (six subjects) in the placebo arm. 
Buse et al. (2004) analyzed 377 randomized subjects with uncontrolled 
type II diabetes that had been treated with sulfonylurea at a maximum dose for 
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three months.  One hundred seventeen of the randomized subjects withdrew due 
to adverse event, investigator decision, protocol violation, loss to follow-up, or 
loss of glucose control as defined in the protocol.  General inclusion criteria were 
a screening fasting plasma glucose concentration of <240 mg/dl, BMI 27-
45kg.m2, HbA1c 7.1-11.0%, and a stable weight (±10%) for three months.  
Subjects were excluded from the study if they had prior use of metformin, 
thiazolidinediones, meglitinides, alpha-glucosidase inhibitors, exogenous insulin 
therapy, or weight-loss drugs within the prior three months.  
All of the participating subjects from Buse et al. were treated with 
sulfonylurea (45% glipizide, 33% glyburide, 1% tolozamide, and 0.3% 
chlorpropamide).  HbA1c values were reduced in all three treatment arms of 
exenatide 10mg and exenatide 5 mg administered twice a day.  The HbA1c 
significantly decreased in the first 12 weeks on both of the exenatide arms while 
the placebo arm had little change.  At week 30, the HbA1c changed from a 
baseline of -0.86 ± 0.11% in the 10 mg exenatide arm and -0.46 ± 0.12% in the 
5mg exenatide arm compared with an increase of 0.12 ± 0.09% in the placebo 
arm (adjusted P • 0.0002 for pair wise comparisons).  The intent-to-treat 
population at week 30 with baseline HbA1c >7% (n=353), 41 subjects (34.2) in 
the 10mg exenatide arm and 31 subjects (26.7%) in the 5mg exenatide arm 
reached an HbA1c • 7%, results that were significantly greater than the placebo 
arm (9 subjects [7.7%]; P•0.0001 for pairwise comparisons).  The evaluable 
population at week 30 with a baseline HbA1c >7% (n=237), 33 subjects (41.3%) 
in the 10mg exenatide arm and 28 subjects (32.6%) in the 5mg exenatide arm 
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reached an HbA1c •7%, and these proportions of evaluable population were 
significantly greater than the placebo group (6 subjects [8.8%]; p• 0.0002 for 
pairwise comparisons).  Fasting glucose concentrations after week 30 in the 10- 
and 5-mg exenatide arms were reduced by -0.6 ± 0.3 and -0.3 ± 0.2 mmol/l from 
baseline, respectively, compared with an increase of 0.4 ± 0.3 mmol/l in the 
placebo arm (P<0.05 vs. placebo for the 10-mg arm only).   Weight loss in both 
the 10- and 5-mg exenatide arms were identified; the 10-mg exenatide arm 
demonstrated a progressive weight loss over the entire 30 weeks, with an end-of-
study weight loss of -1.6± 0.3 kg from baseline (P<0.05 vs placebo).  Subjects in 
the 5-mg exenatide arm experienced a weight loss of -0.9 ± 0.3 from baseline 
(NS vs placebo).  The most frequent adverse event during the study was mild to 
moderate gastrointestinal symptoms.  Nausea was generally described to be mild 
or moderate in intensity and peaked during the initial weeks of dosing (weeks 0-
8), then decreased in incidence thereafter.  The incidence of severe nausea was 
low (5% in the 10-mg exenatide arm, 5% in the 5-mg exenatide arm, and 2% in 
the placebo arm).  There were no severe incidences of hypoglycemic events in 
this study.  The overall incidences of mild to moderate hypoglycemia were 36% 
in the 10-mg exenatide arm, 14% in the 5-mg exenatide arm, and 3% in the 
placebo arm. 
The Zinman et al. (2007) study was a randomized, double blind study with 
a sample size of 233 subjects (exenatide group, n=121; placebo group, n=112) 
with type II diabetes that are sub-optimally controlled with thiazolidinedione 
(TZD).  The study was 16 weeks long with a 2-week, single blind, placebo lead-in 
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period that resulted in 233 patients who were randomly assigned and analyzed in 
the intention-to-treat sample.  The exenatide and placebo group were similar in 
age, body weight, duration of disease, and glycemic control.  At 16 weeks, 
results demonstrated a mean HbA1c decrease of 0.89% ± 0.09% in the 
exenatide group (p<0.001); but a mean of 0.09%±0.10% in the placebo group.  
The mean-between-group difference in HbA1c levels (exenatide minus placebo) 
at week 16 was -0.98% (95% CI, -1.21% to –0.74%; p<0.001). Among per 
protocol patients, 62% of patients in the exenatide group and 16% of patients in 
the placebo group, achieved hemoglobin A1c levels of 7% or less (p < 0.001), 
and 30% and 8% of patients, respectively, achieved hemoglobin A1c levels of 
6.5% or less (P< 0.001). Mean fasting serum glucose levels decreased more in 
the exenatide (intention-to-treat sample) group (mean [± SE] change, -1.59 ± 
0.22mmol/L [-28.6 ± 3.96 mg/dl]), than in the placebo group (mean [± SE] 
change, 0.10 ± 0.21 mmol/L [1.803.78 mg/ dL]). 
The mean-between-group difference in fasting serum glucose level at week 16 
was -1.69 mmol/L (-30.4 mg/dL) (CI, -2.22 to-1.17 mmol/L [-40.0 to -21.1 mg/dL]; 
p< 0.001). The existing oral antihyperglycemic treatment at baseline (TZD alone 
versus TZD plus metformin) did not influence observed changes in HbA1c levels 
(P=0.87 for interaction). Patients treated with exenatide and TZD alone (n=27), 
had mean HbA1c levels that decreased from 7.93% (SD, 0.87%) to 7.15% (SD, 
1.05%), and patients treated with exenatide and TZD in combination with 
metformin (n=90) had mean levels that decreased from 7.88% (SD, 0.92%) to 
7.10% (SD, 0.92%). Patients who received placebo and TZD alone (n=19) had 
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mean HbA1c levels that increased from 7.83% (SD, 0.89%) to 7.90% (SD, 
0.93%), and patients who received placebo and TZD plus metformin (n=86) had 
mean levels that increased from 7.93% (SD, 0.79%) to 8.02% (SD, 1.13%).   
  The most common adverse event from the Zinman et al. (2007) study 
was nausea, which is also the main reason for withdrawal from the study.  
Approximately 9% of the exenatide group and 1% of the placebo group withdrew 
from the study because of nausea.  Most reports of nausea had occurred after an 
increase of dosage from 5mg to 10mg of exenatide twice daily; reports of nausea 
had declined at approximately week 8 from 41 subjects and week 16 from 19 
subjects. The overall incidence of hypoglycemia also was low and similar 
between groups (between-group difference, 3.6 percentage points [CI, 4.6 to 
11.8 percentage points]). No severe hypoglycemia was reported. 
   
 
DISCUSSION 
 Maximizing medication management to improve glycemic control is 
important in the treatment of type II diabetes. New medications and treatment 
regimens are aimed at improving glycemic control and ultimately preventing the 
variety of complications associated with poorly controlled diabetes. In an effort to 
evaluate the outcome of adding exenatide to existing medical management 
regimen, this systematic review studied several published manuscripts.  
The outcomes reviewed included HbA1c, fasting plasma glucose, and 
body weight.  DeFronzo et al. (2005), Buse et al. (2004), and Zinman et al. 
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(2007) all observed notable reductions in these measures during their 
investigations.  The study from Defronzo et al. (2005) demonstrated an overall 
improvement in HbA1c achieving the desired result of less than 7% from nearly 
50% of participants who had taken 10-mg of exenatide.  Subjects who had taken 
5-mg of exenatide also demonstrated a reduction of HbA1c and plasma glucose 
but it was not as effective in taking 10-mg of exenatide.  The 10-mg exenatide 
arm also demonstrated overall weight loss that was coupled with improved 
glycemic control.  It is important to note that the weight loss that was observed 
did not plateau during the 30-week study.  The most common side effect of 
exenatide was dose-related nausea, which occurred in only 3% in the 10-mg 
exenatide arm.  Subjects described their nausea to be mild to moderate in 
intensity, occurring mostly during weeks 4-8. No hypotension was observed in 
Defronzo et al. (2005) study. 
 Buse et al. (2004) also demonstrated similar and consistent results with 
DeFronze et al. (2005) in their 30-week study of exenatide and sulfonylurea.  
They observed long-term use of exenatide at fixed doses of 5 and 10mg twice a 
day, greatly improved glycemia in patients failing sulfonylurea therapy.  The 
biggest difference between Buse and Defronzo studies is the hypoglycemic 
events that occurred more in the Buse et al. (2004) study.  It appears that 
hypoglycemia occurred more readily in subjects who had been taking the 10mg 
dose of exenatide and sulfonylurea.  Events of hypoglycemia were described to 
be mild to moderate in intensity.  It is important to note that when exenatide was 
used in conjunction with metformin in the DeFronzo et al. (2005) study, no 
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hypoglycemia was observed.  It is possible to speculate that the sulfonylurea 
itself is what could have caused the hypoglycemic events.    
 Defronzo et al. (2005) and Buse et al. (2004) both produced adequate 
data demonstrating a reduction of HbA1c and fasting plasma glucose, however, 
during the weeks of 24-30 in all three-treatment arms (placebo, 5-mg, and 10mg 
exenatide) demonstrated a slight increase in HbA1c.  No explanations were 
found in both studies explaining the reason for the increase of HbA1c.  It is 
possible that it was not exenatide related since a slight increase in the placebo 
group was also identified.  The lack of explanation could be potential weakness 
of both studies.   
 The 16-week study conducted by Zinman et al. (2007) demonstrated that 
exenatide in combination with TZD improves HbA1c, fasting blood glucose, and 
postprandial glucose in patients suboptimally controlled with TZD alone or in 
combination with Metformin.  Reduced weight loss had also been a consequence 
by the use of exenatide.  Subjects reported no clinical hypoglycemic events.  The 
most common adverse event reported by subjects was nausea.  The 16-week 
study is prone to criticism because researchers could not assess sustained 
reduction of HbA1c, glucose control and weight loss maintenance from exenatide 
from a short study.  However, it is safe to conclude that a reduction in HbA1c is 
observed in a relatively short study.    
  The Grading of Recommendations Assessment Development and 
Evaluation (Grade) was used in this paper to evaluate the quality of evidence and 
strength of recommendations provided in this study.  All literatures chosen from 
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the DeFronzo et al. (2005), Buse et al. (2004), and Zinman et al. (2007) were 
randomized control trials, which are a “high” type of evidence according to the 
GRADE criteria. All studies of exenatide had achieved their desired outcome of 
decreased HbA1c, fasting glucose and weight loss from a large magnitude of 
participants.  However, higher doses of exenatide demonstrated a greater 
decrease of HbA1c from all studies.  According to these studies that were 
analyzed, exenatide is an effective medication for type II diabetics who have 
maximally used traditional oral hyperglycemic medications.  It is also important to 
note that patients could potentially lose weight with this medication and may 
attract overweight type II diabetics.  The only bias that had been identified in this 
paper is the study from Zinman et al. (2007), which was sponsored by Eli Lilly 
Company, Indianapolis, Indiana.  This bias had downgraded the desired 
outcomes score to “moderate”.  A “moderate” score means that future research 
could have an important impact on data that may or may not change clinical 
effects.  In addition, further research on dose optimizing regimens could be 
evaluated.  The literatures that were discussed in this research paper only 
evaluated the clinical effects of 5mg and 10 mg of exenatide.  Perhaps a longer 
study that titrates exenatide from 5mg to 10mg could potentially find an optimized 
dosing regimen.  Ultimately, this medication scored a “moderate” on the overall 
GRADE of evidence.  This means that clinicians who wish to use exenatide have 
supportive evidence of its safety and clinical efficacy. 
 In summary, this research paper reviewed clinical trials on adding 
exenatide to oral hyperglycemic in sub-optimally controlled type II diabetics. Data 
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demonstrated dose-related subcutaneous administration of exenatide appeared 
to reduce HbA1c, fasting blood glucose and had a positive effect on weight 
reduction.  The biggest concern of exenatide is dose-related nausea that 
occurred during the first few weeks, which gradually improved after the 8th week 
in DeFronzo et al. (2005) and Buse et al. (2004) studies.          
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glucose 
3 RCT Decreased 
fasting 
glucose 
Hig
h 
0 0 0 0 -1 0 0 0 Moderate 
Weight loss 3 RCT Progressiv
e weight 
loss 
Hig
h 
0 0 0 0 -1 0 0 0 Moderate 
Hypoglycemic 
events  
3 RCT No severe 
hypoglycemic 
events, but 
most mild to 
moderate 
hypoglycemic 
events were 
found in the 
sulfonylurea 
study 
Hig
h 
0 0 0 0 -1 0 0 0 Moderate 
